Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosaceaSCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescriptio ...

National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatmen ...

Product Launch and Revenue - EmrosiTM received FDA approval on November 1, 2024, for treating inflammatory lesions of rosacea, with initial supply available in March 2025 and sales promotion starting in April 2025[92]. - Total net product revenue for Q1 2025 was $13.1 million, a slight increase of 1% from $13.0 million in Q1 2024, driven by $2.0 million from EmrosiTM[99]. - EmrosiTM generated $2.1 million in revenue during its first quarter of commercial launch, offsetting declines in other products like Accutane, which saw a 37% decrease in revenue[99]. - Gross-to-net sales accruals increased to $15.5 million as of March 31, 2025, up from $9.9 million a year earlier, attributed to coupon rebate allowances for EmrosiTM[100]. Financial Performance - Loss from operations improved by 67%, decreasing from $10.1 million in Q1 2024 to $3.3 million in Q1 2025[98]. - The company reported a net loss of $4.1 million for Q1 2025, a 61% reduction compared to a net loss of $10.4 million in Q1 2024[98]. - Operating expenses decreased by 29% from $23.1 million in Q1 2024 to $16.5 million in Q1 2025, primarily due to a 100% reduction in research and development expenses[98]. - Selling, general, and administrative expenses rose by 26% from $8.4 million in Q1 2024 to $10.6 million in Q1 2025[98]. - Interest expense increased by 63% from $548,000 in Q1 2024 to $891,000 in Q1 2025[98]. - Cost of goods sold decreased by $1.2 million, or 20%, to $4.8 million for the three-month period ended March 31, 2025, from $6.0 million for the same period in 2024[101]. Research and Development - Research and development costs were nil in Q1 2025, compared to $7.9 million in Q1 2024, which included Emrosi pre-approval project expenses[103]. - Amortization of acquired intangible assets increased by $0.3 million, or 31%, to $1.1 million for the three-month period ended March 31, 2025, driven by the addition of the Emrosi acquired intangible asset[102]. Cash Flow and Financing - Cash and cash equivalents increased to $21.1 million at March 31, 2025, compared to $20.3 million at December 31, 2024[106]. - Net cash used in operating activities decreased by $2.2 million to $2.8 million for the three-month period ended March 31, 2025, driven by a decrease in net loss[114]. - Net cash flows provided by financing activities increased by $2.0 million to $3.6 million for the three-month period ended March 31, 2025, primarily due to net proceeds from common stock issuances[115]. - Total cash requirements under the SWK Credit Facility include $7.3 million in interest and $25.0 million in principal payments[117]. - The company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives[108]. Industry and Market Risks - The company operates in a heavily regulated industry, with significant risks related to product development, competition, and market acceptance[89].

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced earnings of $0.08, delivering a surprise of 136.36%.Over the last four quarters, the company ...

Journey Medical Corp (DERM) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Jaclyn Jaffe - Senior Director of Corporate OperationsClaude Maraoui - Co-Founder, President and Chief Executive OfficerJoseph Benesch - CFORamsey Alloush - COO & General CounselSrinivas Sidgiddi - Vice President - Research & Development Conference Call Participants Scott Henry - Managing Director & Senior Research AnalystKalpit Patel - Senior Biotech Research AnalystThomas Flaten - Senior Research Analyst Operat ...

Journey Medical Corp (DERM) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to Journey Medical's First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Participants of this call are advised that the audio of this conference call is being broadcast live I would now like to turn the call over to Jacqueline Jaffe, the company's Senior D ...

Exhibit 99.1 Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Of to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conf ...

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ( ...

About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive exp ...

Company Overview - Journey Medical Corporation (DERM) shares increased by 9.1% to $7.19 in the last trading session, with a notable trading volume, contributing to a 30.2% gain over the past four weeks [1] - The rise in stock price is linked to positive investor sentiment regarding the growing sales of its branded and generic dermatological drugs [1] Financial Expectations - The company is projected to report a quarterly loss of $0.24 per share, reflecting a year-over-year change of +54.7% [2] - Expected revenues are $11.89 million, which is an 8.8% decline from the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Journey Medical has been revised down by 1100% over the last 30 days [3] - A negative trend in earnings estimate revisions typically does not lead to stock price appreciation, indicating potential caution for future performance [3] Industry Context - Journey Medical is part of the Zacks Medical - Drugs industry, where Assertio (ASRT) has seen a decline of 15.7% over the past month, closing at $0.63 [3] - Assertio's consensus EPS estimate has changed by -150% over the past month, indicating a significant downturn compared to the previous year [4]